CY2428B1 - At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys. - Google Patents
At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys.Info
- Publication number
- CY2428B1 CY2428B1 CY0400015A CY0400015A CY2428B1 CY 2428 B1 CY2428 B1 CY 2428B1 CY 0400015 A CY0400015 A CY 0400015A CY 0400015 A CY0400015 A CY 0400015A CY 2428 B1 CY2428 B1 CY 2428B1
- Authority
- CY
- Cyprus
- Prior art keywords
- renal failure
- preventing
- pct
- receptor antagonists
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH282595 | 1995-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY2428B1 true CY2428B1 (en) | 2004-11-12 |
Family
ID=4242452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY0400015A CY2428B1 (en) | 1995-10-06 | 2004-02-27 | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6071931A (pt) |
EP (1) | EP0853477B1 (pt) |
JP (3) | JPH11513395A (pt) |
AT (1) | ATE225657T1 (pt) |
AU (1) | AU7213296A (pt) |
BR (1) | BR9611007A (pt) |
CA (1) | CA2232663C (pt) |
CY (1) | CY2428B1 (pt) |
DE (1) | DE69624253T2 (pt) |
DK (1) | DK0853477T3 (pt) |
ES (1) | ES2184892T3 (pt) |
MY (1) | MY119312A (pt) |
PT (1) | PT853477E (pt) |
TW (1) | TW445147B (pt) |
WO (1) | WO1997013513A1 (pt) |
ZA (1) | ZA968378B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
IT1295405B1 (it) * | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
JP5187991B2 (ja) * | 1997-10-17 | 2013-04-24 | アーク・セラピューティックス・リミテッド | レニン−アンジオテンシン系の阻害剤の使用 |
WO2000038676A1 (en) | 1998-12-23 | 2000-07-06 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
SE9902597D0 (sv) * | 1999-07-06 | 1999-07-06 | Astra Ab | New use |
BR0111868A (pt) * | 2000-06-22 | 2003-07-01 | Novartis Ag | Composições farmacêuticas |
CA2415962C (en) * | 2000-07-19 | 2010-07-06 | Novartis Ag | Valsartan salts |
WO2002015935A1 (fr) * | 2000-08-25 | 2002-02-28 | Takeda Chemical Industries, Ltd. | Agents de reduction du fibrinogene |
AU2003223637A1 (en) * | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
WO2005097109A1 (en) * | 2004-04-01 | 2005-10-20 | Daniel Batlle | Methods for achieving a protective ace2 expression level |
US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物 |
RU2456615C1 (ru) * | 2011-03-25 | 2012-07-20 | Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации | Способ профилактики отторжения трансплантата трупной почки |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
DE69034103T2 (de) * | 1989-06-14 | 2004-07-15 | Smithkline Beecham Corp. | Imidazoalkensäure |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
PH30484A (en) * | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
NZ237476A (en) * | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) * | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5196537A (en) * | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
WO1993020816A1 (en) * | 1992-04-13 | 1993-10-28 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
EP0720477A1 (en) * | 1992-09-09 | 1996-07-10 | Vanderbilt University | Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation |
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
-
1996
- 1996-09-24 AU AU72132/96A patent/AU7213296A/en not_active Abandoned
- 1996-09-24 CA CA002232663A patent/CA2232663C/en not_active Expired - Fee Related
- 1996-09-24 PT PT96933369T patent/PT853477E/pt unknown
- 1996-09-24 US US09/051,345 patent/US6071931A/en not_active Expired - Lifetime
- 1996-09-24 AT AT96933369T patent/ATE225657T1/de active
- 1996-09-24 DE DE69624253T patent/DE69624253T2/de not_active Expired - Lifetime
- 1996-09-24 JP JP9514668A patent/JPH11513395A/ja not_active Withdrawn
- 1996-09-24 DK DK96933369T patent/DK0853477T3/da active
- 1996-09-24 ES ES96933369T patent/ES2184892T3/es not_active Expired - Lifetime
- 1996-09-24 WO PCT/EP1996/004162 patent/WO1997013513A1/en active IP Right Grant
- 1996-09-24 BR BR9611007A patent/BR9611007A/pt not_active Application Discontinuation
- 1996-09-24 EP EP96933369A patent/EP0853477B1/en not_active Expired - Lifetime
- 1996-09-24 MY MYPI96003925A patent/MY119312A/en unknown
- 1996-09-25 TW TW085111691A patent/TW445147B/zh not_active IP Right Cessation
- 1996-10-04 ZA ZA968378A patent/ZA968378B/xx unknown
-
2004
- 2004-02-27 CY CY0400015A patent/CY2428B1/xx unknown
-
2007
- 2007-10-02 JP JP2007258682A patent/JP2008019273A/ja not_active Ceased
-
2011
- 2011-08-12 JP JP2011176948A patent/JP2011256195A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2184892T3 (es) | 2003-04-16 |
JP2011256195A (ja) | 2011-12-22 |
JPH11513395A (ja) | 1999-11-16 |
EP0853477A1 (en) | 1998-07-22 |
JP2008019273A (ja) | 2008-01-31 |
PT853477E (pt) | 2003-01-31 |
US6071931A (en) | 2000-06-06 |
TW445147B (en) | 2001-07-11 |
EP0853477B1 (en) | 2002-10-09 |
BR9611007A (pt) | 1999-07-13 |
DK0853477T3 (da) | 2003-02-10 |
ATE225657T1 (de) | 2002-10-15 |
DE69624253D1 (de) | 2002-11-14 |
WO1997013513A1 (en) | 1997-04-17 |
DE69624253T2 (de) | 2003-08-07 |
CA2232663A1 (en) | 1997-04-17 |
MY119312A (en) | 2005-05-31 |
ZA968378B (en) | 1997-04-07 |
CA2232663C (en) | 2008-04-08 |
AU7213296A (en) | 1997-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2428B1 (en) | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys. | |
LU93229I2 (fr) | "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate" | |
EP0826671A4 (en) | HETEROCYCLIC AMIDE DERIVATIVES AND THEIR MEDICAL USE | |
ATE196295T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
NZ509632A (en) | Use of EP4 receptor selective agonists (5-(3-hydroxy-4-phenyl-but-1-enyl)-1-[6-(1H-tetrazol-5-yl)-hexyl]-pyrrolidin-2-one or 7-[2-(3-hydroxy-4-phenyl-butyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid for the treatment of acute and chronic renal failure | |
EP0805149A4 (en) | NEW 2,3-DICETOPIPERAZINE DERIVATIVE OR SALT THEREOF | |
CY2567B1 (en) | Treatment of normotensive glaucoma with angiotensin II antagonists | |
PL324890A1 (en) | Halogenbenzimidazoles and their application as microbicides | |
HU9502660D0 (en) | New heterocyclic compounds, their preparation and their use | |
GR3029845T3 (en) | Pvdf adhesion binder, use thereof as a barrier material, and resulting materials | |
GB9602029D0 (en) | New heterocyclic compounds | |
NO981856L (no) | Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling av amyotrof lateral sclerose | |
IE892596L (en) | Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties | |
GB9305641D0 (en) | Therapeutic agents | |
CA2371554A1 (en) | Pharmaceutical composition comprising an angiotensin ii antagonist for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy | |
SI1176960T1 (en) | Synergistic combination comprising roflumilast and a pde-3 inhibitor | |
BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
PT706395E (pt) | Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo | |
WO2002014532A3 (en) | Method for identifying modulators of 'mec'-induced functions of ccr3 and/or ccr10 | |
TW200518747A (en) | Additional pharmaceutical use | |
MA23130A1 (fr) | Procede de preparation d'un derive de benzylimidazopyridine servant d'antagoniste des recepteurs de l'angiotensine ii. | |
HK1038886A1 (en) | Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors for the preparation of a pharmaceutical composition for treatment of kidney disorder. |